Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | MGMT | P16455 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | CDC7 | O00311 | 2/20 | 0.46 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.46 |
| ▸ | MPO | P05164 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29661259 | 1.00 | PIN1 (0.46) | PIN1CYP3A4MGMTLMNACYP1A2 | |
| 6-O-Benzylguanine SCHEMBL29405347 | 0.83 | MGMT (0.63) | PIN1CYP3A4MGMTLMNACYP1A2 | |
| SCHEMBL8959020 | 0.83 | MGMT (0.46) | PIN1CYP3A4MGMTLMNACYP1A2 | |
| SCHEMBL14998811 | 0.83 | DYRK1A (0.48) | PIN1CYP3A4MGMTLMNACYP1A2 | |
| 6-O-Benzylguanine SCHEMBL600698 | 0.83 | MGMT (0.63) | PIN1CYP3A4MGMTLMNACYP1A2 | |
| 6-O-Benzylguanine SCHEMBL4631743 | 0.82 | MGMT (0.61) | PIN1CYP3A4MGMTLMNACYP1A2 | |
| SCHEMBL16549303 | 0.79 | PIN1 (0.44) | PIN1LMNA | |
| SCHEMBL20119742 | 0.79 | SMN1; SMN2 (0.46) | MGMTLMNACYP1A2TSHRHTR2A | |
| SCHEMBL821766 | 0.78 | CDC7 (0.60) | PIN1CYP3A4MGMTLMNACYP1A2 | |
| SCHEMBL21591842 | 0.78 | MPO (0.43) | PIN1CYP3A4MGMTLMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4801710-A | Regioselective synthesis of 9-substituted purine acyclonucleoside derivatives | MERCK & CO., INC. (US) | 1989-01-31 | — | — | US | claimed |
| EP-0184473-A1 | Regioselective synthesis of 9-substituted purine acyclonucleoside derivatives | MERCK & CO. INC. (US) | 1986-06-11 | — | — | EP | claimed |
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | ILDONG PHARMACEUTICAL CO LTD (KR) | 2025-12-25 | — | — | US | disclosed |
| US-20250195498-A1 | INHIBITOR OF CELLULAR PURINE NUCLEOTIDE SALVAGE PATHWAY ENZYME FOR USE IN THE TREATMENT AND/OR PREVENTION OF HELICOBACTER PYLORI INFECTION AND/OR DISEASE ASSOCIATED WITH SUCH INFECTION AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | UNIWERSYTET WARSZAWSKI (PL) | 2025-06-19 | — | — | US | disclosed |
| EP-4556476-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | Ildong Pharmaceutical Co., Ltd. (KR) | 2025-05-21 | — | — | EP | disclosed |
| WO-2023177312-A2 | INHIBITOR OF CELLULAR PURINE NUCLEOTIDE SALVAGE PATHWAY ENZYME FOR USE IN THE TREATMENT AND/OR PREVENTION OF HELICOBACTER PYLORI INFECTION AND/OR DISEASE ASSOCIATED WITH SUCH INFECTION AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | UNIWERSYTET WARSZAWSKI (PL) | 2023-09-21 | — | — | WO | disclosed |
| US-20080108612-A1 | 6-(phenylmethyl)amino-1H-purine; chaperone protein inhibitor; anticarcinogenic agent | AVENTIS PHARMA S.A. (FR) | 2008-05-08 | — | — | US | disclosed |
| US-20080108612-A1 | 6-(phenylmethyl)amino-1H-purine; chaperone protein inhibitor; anticarcinogenic agent | AVENTIS PHARMA S.A. (FR) | 2008-05-08 | — | — | US | disclosed |
| EP-0538332-B1 | POLYCYCLIC GUANINE DERIVATIVES | SCHERING CORP (US) | 1997-07-23 | — | — | EP | disclosed |
| US-5393755-A | Hypotensive agents, enzyme inhibitors | SCHERING CORPORATION (US) | 1995-02-28 | — | — | US | disclosed |
| EP-0538332-A1 | POLYCYCLIC GUANINE DERIVATIVES. | SCHERING CORP (US) | 1993-04-28 | — | — | EP | disclosed |
| WO-1991019717-A1 | POLYCYCLIC GUANINE DERIVATIVES | SCHERING CORPORATION (US) | 1991-12-26 | — | — | WO | disclosed |
| US-4801710-A | Regioselective synthesis of 9-substituted purine acyclonucleoside derivatives | MERCK & CO., INC. (US) | 1989-01-31 | — | — | US | disclosed |
| EP-0184473-A1 | Regioselective synthesis of 9-substituted purine acyclonucleoside derivatives | MERCK & CO. INC. (US) | 1986-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108612-A1 | 6-(phenylmethyl)amino-1H-purine; chaperone protein inhibitor; anticarcinogenic agent | HSP90B1, HSPBP1, HSP90AB2P | PIN1 2550/4885CYP3A4 4040/4885MGMT 880/4885 |
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | GBA1, PIKFYVE, MAN2B1 | PIN1 4709/4885CYP3A4 4110/4885MGMT 3468/4885 |
| US-20250195498-A1 | INHIBITOR OF CELLULAR PURINE NUCLEOTIDE SALVAGE PATHWAY ENZYME FOR USE IN THE TREATMENT AND/OR PREVENTION OF HELICOBACTER PYLORI INFECTION AND/OR DISEASE ASSOCIATED WITH SUCH INFECTION AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | PNP, ITPA, NUDT5 | PIN1 816/4885CYP3A4 2586/4885MGMT 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.